EQRx could potentially lower drug prices, but only because of competition and not out of the goodness of their hearts. Few companies deliberately lower profits

EQRx could potentially lower drug prices, but only because of competition and not out of the goodness of their hearts. Few companies deliberately lower profits without exogenous pressure. If a company has a 20 year monopoly on a drug and a similar drug shows up before the patent expires, competition will somewhat bring down prices. I say somewhat because healthcare is a convoluted opaque mess.